Metoclopramide
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Antiemetics | Metoclopramide | 5mg PO/IV Q6H PRN | Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 299.8 | 10-22 | 2.5-4 | 14-15 | 40 | 2-3.4 | 91.0 ± 15.9 |
minimal (Low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Bateman DN, Gokal R, Dodd TRP, Blain PG. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol 1981;19,437-41.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01233
- Lehmann CR, Heironimus JD, Collins MB, O'Neil TJ, Pierson WP, Crowe JT, et al. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharmacol Ther 1985;37:284-9.
- Wright MR, Axelson JE, Rurak DW, McErlane B, McMorland GH, Ongley RC, Tam YK, et al. Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure. Br J Clin Pharmacol 1988;26:474-7.